ISRCTN16055614 https://doi.org/10.1186/ISRCTN16055614

Phase I trial; HMR code: 24-003

Submission date 05/08/2024	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 12/08/2024	**Overall study status** Deferred	
Last Edited 06/01/2025	**Condition category** Other	

Plain English summary of protocol
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Principal investigator

Contact name
Dr Adeep Puri

Contact details
Hammersmith Medicines Research Limited
Cumberland Avenue
Park Royal
London
United Kingdom
NW10 7EW
+44 20 8961 4130
rec@hmrlondon.com

Type(s)
Public, Scientific

Contact name
Dr Jeff Kent

Contact details
455 E. Eisenhower Parkway
Suite 300 PMB 1048
Ann Arbor
United States of America

MI 48108
+1 734 887 9192
info@slingtx.com

Additional identifiers

Integrated Research Application System (IRAS)
1010220

Protocol serial number
HMR code: 24-003; Sponsor code: SLG-TED-101

Study information

Scientific Title
Phase I trial; HMR code: 24-003 [The full scientific title will be published within 30 months after the end of the trial]

Study objectives
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 30/07/2024, London – Surrey Borders Research Ethics Committee (Equinox House, City Link, Nottingham, NG2 4LA, United Kingdom; +44 207 104 8057; surreyborders.rec@hra.nhs.uk), ref: 24/LO/0492

Primary study design
Interventional

Study design
Pharmacokinetic and bioavailability study in up to 20 healthy volunteers

Study type(s)
Other

Health condition(s) or problem(s) studied
Healthy volunteers

Interventions
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date
08/08/2025

Eligibility

Key inclusion criteria
Healthy volunteer

Participant type(s)
Healthy volunteer

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Key exclusion criteria
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment
14/08/2024

Date of final enrolment
08/05/2025

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Hammersmith Medicines Research Limited
Cumberland Avenue
London
United Kingdom
NW10 7EW

Sponsor information

Organisation
Sling Therapeutics, Inc.

Funder(s)

Funder type
Industry

Funder Name
Sling Therapeutics, Inc.

Results and Publications

Individual participant data (IPD) sharing plan
The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary
Not expected to be made available